Satsuma Pharmaceuticals
STSA
STSA was delisted on the 7th of June, 2023.
32 hedge funds and large institutions have $94.2M invested in Satsuma Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 7 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
1.04% less ownership
Funds ownership: 73.19% → 72.15% (-1%)
11% less funds holding
Funds holding: 36 → 32 (-4)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
66% less capital inflows, than outflows
Capital inflows: $1.1M | Capital outflows: $3.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Samlyn Capital
New York
|
+$526K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$206K |
| 3 |
JP Morgan Chase
New York
|
+$166K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$58.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$53.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$1.8M |
| 2 |
Walleye Capital
New York
|
-$389K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$311K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$263K |
| 5 |
Two Sigma Investments
New York
|
-$132K |
STSA Hedge Fund Activity: Q2 2022 in Review
32 of the 5,961 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals (STSA) for Q2 2022, worth a combined $94.2M — up 7.5% from $87.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of STSA and 3 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Samlyn Capital, adding an estimated $526K. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $1.8M sold.
- 32 institutional investors held Satsuma Pharmaceuticals (STSA) as of Q2 2022, down from 36 in Q1 2022.
- Funds reported $94.2M of Satsuma Pharmaceuticals stock for Q2 2022, up 7.5% quarter-over-quarter.
- 3 funds opened new Satsuma Pharmaceuticals positions in Q2 2022 and 7 closed out, a net change of -4 holders.
- The largest Satsuma Pharmaceuticals buyer in Q2 2022 was Samlyn Capital, an estimated $526K added.
- The largest Satsuma Pharmaceuticals seller in Q2 2022 was Ghost Tree Capital, an estimated $1.8M sold.
Based on aggregated 13F filings for Q2 2022.